Abstract:To determine whether low ventricular filling pressures are a clinically relevant etiology of unexplained dyspnea on exertion, a database of 619 consecutive, clinically indicated invasive cardiopulmonary exercise tests (iCPETs) was reviewed to identify patients with low maximum aerobic capacity (V O 2 max) due to inadequate peak cardiac output (Qtmax) with normal biventricular ejection fractions and without pulmonary hypertension (impaired: n = 49, V O 2 max = 53% predicted [interquartile range (IQR): 47%-64%],… Show more
“…Finally, the relative syndrome-dependent inactivity among POTS patients might hypothetically lead to a reversal or gross disturbance in circadian patterns of GH release. However, deconditioning as an underlying pathophysiology of POTS and to possibly related syndromes such as chronic fatigue syndrome has not been supported by recent studies, and other mechanisms such as low ventricular filling have been proposed [34,35]. It remains to be demonstrated if physical training may reverse GH level abnormality.…”
Background: Postural orthostatic tachycardia syndrome (POTS) is a variant of cardiovascular (CV) autonomic disorder of unknown etiology characterized by an excessive heart rate increase on standing and orthostatic intolerance. In this study we sought to identify novel CV biomarkers potentially implicated in POTS pathophysiology. Methods: We conducted a nested case-control study within the Syncope Study of Unselected Population in Malmö (SYSTEMA) cohort including 396 patients (age range, 15-50 years) with either POTS (n = 113) or normal hemodynamic response during passive head-up-tilt test (n = 283). We used a targeted approach to explore changes in cardiovascular proteomics associated with POTS through a sequential two-stage process including supervised principal component analysis and univariate ANOVA with Bonferroni correction. Results: POTS patients were younger (26 vs. 31 years; p < 0.001) and had lower BMI than controls. The discovery algorithm identified growth hormone (GH) and myoglobin (MB) as the most specific biomarker fingerprint for POTS. Plasma level of GH was higher (9.37 vs 8.37 of normalised protein expression units (NPX); p = 0.002), whereas MB was lower (4.86 vs 5.14 NPX; p = 0.002) in POTS compared with controls. In multivariate regression analysis, adjusted for age and BMI, and stratified by sex, lower MB level in men and higher GH level in women remained independently associated with POTS. Conclusions: Cardiovascular proteomics analysis revealed sex-specific biomarker signature in POTS featured by higher plasma level of GH in women and lower plasma level of MB in men. These findings point to sex-specific immune-neuroendocrine dysregulation and deconditioning as potentially key pathophysiological traits underlying POTS.
“…Finally, the relative syndrome-dependent inactivity among POTS patients might hypothetically lead to a reversal or gross disturbance in circadian patterns of GH release. However, deconditioning as an underlying pathophysiology of POTS and to possibly related syndromes such as chronic fatigue syndrome has not been supported by recent studies, and other mechanisms such as low ventricular filling have been proposed [34,35]. It remains to be demonstrated if physical training may reverse GH level abnormality.…”
Background: Postural orthostatic tachycardia syndrome (POTS) is a variant of cardiovascular (CV) autonomic disorder of unknown etiology characterized by an excessive heart rate increase on standing and orthostatic intolerance. In this study we sought to identify novel CV biomarkers potentially implicated in POTS pathophysiology. Methods: We conducted a nested case-control study within the Syncope Study of Unselected Population in Malmö (SYSTEMA) cohort including 396 patients (age range, 15-50 years) with either POTS (n = 113) or normal hemodynamic response during passive head-up-tilt test (n = 283). We used a targeted approach to explore changes in cardiovascular proteomics associated with POTS through a sequential two-stage process including supervised principal component analysis and univariate ANOVA with Bonferroni correction. Results: POTS patients were younger (26 vs. 31 years; p < 0.001) and had lower BMI than controls. The discovery algorithm identified growth hormone (GH) and myoglobin (MB) as the most specific biomarker fingerprint for POTS. Plasma level of GH was higher (9.37 vs 8.37 of normalised protein expression units (NPX); p = 0.002), whereas MB was lower (4.86 vs 5.14 NPX; p = 0.002) in POTS compared with controls. In multivariate regression analysis, adjusted for age and BMI, and stratified by sex, lower MB level in men and higher GH level in women remained independently associated with POTS. Conclusions: Cardiovascular proteomics analysis revealed sex-specific biomarker signature in POTS featured by higher plasma level of GH in women and lower plasma level of MB in men. These findings point to sex-specific immune-neuroendocrine dysregulation and deconditioning as potentially key pathophysiological traits underlying POTS.
“…52 Many patients with HFpEF will have low LV filling pressures at rest requiring assessment with exercise. 37,38,53 iCPET is also required to confirm the diagnosis of EiPH. 54 Figure 3, left column, demonstrates the typical findings in an EiPH patient with normal resting hemodynamics but increased mPAP, PVR, V E/V CO 2, and reduced V O 2 max and V O 2 /HR.…”
Background: Most pulmonary vascular disease (PVD) is poorly modifiable and incurable even with effective therapy. Therefore, adaptation to stress, the reserve of the cardiopulmonary system, is important for assessment of patient function and prognosis. Methods that assess the adaptation to stress, especially exercise, provide valuable insight into diagnosis, prognosis, and response to therapy. Implications for Clinicians: We provide a comprehensive review of the indications, methodology, and interpretation, as well as practical information of the forms of provocative testing in PVD. We include 6-minute walk testing, noninvasive cardiopulmonary exercise testing (CPET), invasive CPET, and additional forms, including volume loading. Conclusions: Through a clear understanding of the methodology in the assessment of PVD, the clinician can determine which of these "tools of the trade" are best suited to the individual patient and situation.
“…However, a more recent study has shown that deconditioning is not the primary underlying mechanism for POTS. Oldham and colleagues 10 showed that exercise intolerance does not result from a lack of enough exercise, but from low ventricular filling pressures even during maximum effort.…”
he term postural orthostatic tachycardia syndrome (POTS) was first used by a team of researchers from Mayo Clinic led by neurologist Philip Low, in 1993. 1 However, the disorder was not new; over the last 160 years, it has been known by many different names, such as neurocirculatory asthenia, orthostatic tachycardia, and orthostatic intolerance. 2 Patients with POTS can be misdiagnosed as having severe anxiety, panic disorder, or chronic fatigue syndrome, because of their similar clinical features. 3
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.